In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Precision Genome Engineering Inc.

Division of bluebird bio Inc.
www.pregenen.com

Latest From Precision Genome Engineering Inc.

Bluebird Casts Wide Partnering Net To Keep Advancing Cell Therapy

Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.

Business Strategies Deals

Gene Editing: In Vivo In Waiting

Gene editing technologies could pose a challenge to gene therapy, bringing new capabilities such as correction of genes or insertion of novel genes at precise genome locations. Various technical barriers remain to maximizing the technique's efficiency, but long-term in vivo applications could transform treatment of a wide range of diseases.

BioPharmaceutical

Deals Shaping The Medical Industry, September 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Pregenen
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • bluebird bio Inc.
  • Senior Management
  • Jorfan Jarjour, PhD, Director Research & Dev.
    Alexander Astrakhan, PhD, Director Pre-Clinical Dev
    Laurie Beitz, MD, COO & co-founder
  • Contact Info
  • Precision Genome Engineering Inc.
    Phone: (206) 812-1512
    454 N 34th Street
    Seattle, WA 98103
    USA
UsernamePublicRestriction

Register